The goal of this clinical study is to establish if the use of public health-related messages, designed and disseminated to a targeted population, will result in tangible improvements in patient outcomes and healthcare practices.
Specific health-related messages oriented towards patients, through their biological results and HealthCare Professionals (HCPs), will be sent to participants included in the intervention group. The control group will not receive any health-related message (routine care).
The aim is to evaluate if this intervention leads to differences in Major Adverse Renal and Cardiovascular Events (MARCE), compared to routine care (no dissemination of health messages) in patients suffering in diabetes and renal failure.
Subject attending a ML participating to the study
Subject presenting a HbA1c ≥ 6.5% and an estimated GFR (CKD-EPI formula) in the range 60 to 15 ml/min (included) and/or albumin to creatinine ratio ≥ 300 mg albumin/g creatinine (or 30 mg/mmol creatinine), on the same biological determination.
Subject previously identified as opposed to the use of their medical data and/or access of their SNDS data,
Subject not registered to the French social security system,
Subject with estimated GFR < 15 ml/min on the day of inclusion
Nantes University Hospital
Lead sponsor
Hospices Civils de Lyon
Collaborator
University Hospital, Toulouse
Collaborator
University Hospital, Tours
Collaborator
Biogroup Laboratoire de biologie médicale
Collaborator
Santé publique France-InVS (Institut National de Veille sanitaire)
Collaborator